Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2a and Hirschsprung disease

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 9, 1998, Pages 3361-3364

  Borrego, Salud ^a   Eng, Charis ^b   Sánchez, Beatriz ^a   Sáez, María Eugenia ^a   Navarro, Elena ^a   Antiñolo, Guillermo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAMILIAL CANCER; GENE MUTATION; HIRSCHSPRUNG DISEASE; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; SIPPLE SYNDROME; THYROID CARCINOMA;

AGED; CHILD, PRESCHOOL; CYSTEINE; DNA; DROSOPHILA PROTEINS; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; HIRSCHSPRUNG DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PEDIGREE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0031741050     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.9.3361     Document Type: Review

References (36)

1. Eng C, Clayton D, Schuffenecker I, et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA. 276:1575-1579.
2. Attié T, Pelet A, Edery P, et al. 1995 Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet. 4:1381-1386.
3. Angrist M, Bolk S, Thiel B, et al. 1995 Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet. 4:821-830.
4. Yin L, Barone V, Seri M, et al. 1994 Heterogeneity and low detection rate of RET mutations in Hirschsprung disease. Eur J Hum Genet. 2:272-280.
5. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. 1988 Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 3:571-578.
6. Davies AM, Dixon JE, Fox GM, et al. 1997 Nomenclature of GPI-linked receptors for the GDNF ligand family. Neuron. 19:485.
7. Durbec P, Marcos-Gutierrez CV, Kilkenny C, et al. 1996 GDNF signalling through the Ret receptor tyrosine kinase. Nature. 381:789-793.
8. Vega QC, Worby CA, Lechner MS, Dixon JE, Dressler GR. 1996 Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morfogenesis. Proc Natl Acad Sci USA. 93:10657-10661.
9. Sanicola M, Hession C, Worley D, et al. 1997 Glial cell line-derived neurotrophic factor-dependet RET activation can be mediated by two different cell-surface accesory proteins. Proc Natl Acad Sci USA. 94:6238-6243.
10. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. 1996 Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature. 384:467-470.
11. Baloh RH, Tansey MG, Golden JP, et al. 1997 TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron. 18:793-802.
12. Buj-Bello A, Adu J, Pinon LG, et al. 1997 Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase. Nature. 387:721-724.
13. Klein RD, Sherman D, Ho WH, et al. 1997 A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature. 387:717-721.
14. Marsh DJ, Zheng Z, Arnold A, et al. 1997 Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors. J Clin Endocrinol Metab. 82:3025-3028.
15. Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A. 1996 Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat Genet. 14:341-343.
16. Ivanchuk SM, Myers SM, Eng C, Mulligan L. 1996 De novo mutations of GDNF, ligand for the RET/GDNFR-α receptor complex, in Hirschsprung disease. Hum Mol Genet. 5:2023-2026.
17. Salomon R, Attié T, Pelet A, et al. 1996 Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease. Nat Genet. 14:345-347:1996.
18. Mulligan LM, Eng C, Attié T, et al. 1994 Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 3:2163-2167.
19. Borst MJ, VanCamp JM, Peacock ML, Decker RA. 1995 Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery. 117:386-391.
20. Caron P, Attié T, David D, et al. 1996 C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Clin Endocrinol Metab. 81:2731-2733.
21. Peretz H, Luboshitsky R, Baron E, et al. 1997 Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum Mutat. 10:155-159.
22. Decker RA, Peacock ML, Watson P. 1998 Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet. 7:129-134.
23. Dracopoli NC, Haines JL, Korf BR, et al, eds. 1994 Current protocols in human genetics. Boston: Wiley and Sons.
24. Mulligan LM, Kwok JBJ, Healey CS, et al. 1993 Germline mutations of the RET proto-oncogene in multoiple endocrine neoplasia type 2A. Nature. 363:458-460.
25. Mulligan LM, Eng C, Healey CS, et al. 1994 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 6:70-74.
26. Eng C, Smith DP, Mulligan LM, et al. 1994 Point mutations within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 3:237-241.
27. Ceccherini I, Hofstra RMW, Luo Y, et al. 1994 DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene. 9:3025-3029.
28. Hofstra RMW, Landsvater RM, Ceccherini I, et al. 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367:375-376.
29. Myers SM, Eng C, Ponder BA, Mulligan LM. 1995 Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene. 11:2039-2045.
30. Rodien P, Jeunemaitre X, Dumont C, Beldjord C, Plouin PF. 1997 Genetic alterations of the RET proto-oncogene in familial and sporadic pheocromocytomas. Horm Res. 47:263-268.
31. Sáez ME, Sánchez B, Antiñolo G, Borrego S. 1998 Identification of a rare polymorphism, S836S, in the tyrosine kinase domain of RET proto-oncogene. Hum Mutat. 11:416.
32. Ito S, Iwashita T, Asai N, et al. 1997 Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res. 57:2870-2872.
33. Puffenberger EG, Hosoda K, Washington SS, et al. 1994 A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell. 79:1257-1266.
34. Chakravarti A. 1996 Endothelin receptor-mediated signaling in Hirschsprung disease. Hum Mol Genet. 5:303-307.
35. Richard I, Beckmann JS. 1995 How neutral are synonymous codon mutations? Nat Genet. 10:259.
36. Takahashi M, Buma Y, Hiai H. 1989 Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene. 4:805-806.